Gabapentin Step Therapy Policy
Cigna step therapy policy that requires trial of a Step 1 gabapentin product (generic gabapentin capsules, tablets, or oral solution) before coverage of Step 2 products (Gabarone, Gralise brand/generic, Horizant, Neurontin). Approvals are for 1 year.
Annual Revision - Review Date 02/05/2025; Summary of Changes = Gabarone tablets: Added to Step 2 products (noted in history).
Summary of changes and key points
This is a Cigna Step Therapy policy that requires a trial of a Step 1 gabapentin product (generic gabapentin capsules, tablets, or oral solution) before coverage of Step 2 products (Gabarone, Gralise brand/generic, Horizant, Neurontin). Note that ER products are not interchangeable with other gabapentin products due to different pharmacokinetic profiles. Annual Revision - Review Date 02/05/2025; Summary of Changes = Gabarone tablets: Added to Step 2 products (noted in history). This revision is not a material change (has_material_change = false) and the policy coverage stance is mixed.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.